Biological Bank for Atrial Fibrillation and Stroke

Recruiting

• Conditions: Stroke; Atrial Fibrillation
• Interventions: Genetic: Blood taken

• Registration Number: NCT03611816
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.

According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.

The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-01-31
• Study Start: 2018-04-23
• Study First Submitted QC: 2018-07-26
• Study First Posted: 2018-08-02
• Status Verified: 2024-04
• Last Update Submitted: 2024-10-22
• Last Update Posted: 2024-10-24
• Primary Completion: 2029-04-23
• Study Completion: 2029-04-23

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1a	Blood taken	Patient with atrial fibrillation and without stroke history.
Group 1b	Blood taken	Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
Group 1c	Blood taken	Patient with atrial fibrillation and with stroke history.
Group 2	Blood taken	Patients aged over 80 years old and without history of atrial fibrillation.
Group 3	Blood taken	Patient with cryptogenic stroke or transient ischemic attack history before the age of 50.

Primary Outcome Measures

Name	Time	Method
Quality of Plasma sample	1 day (the day of the storage)	Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation.
Quality of DNA sample	1 day (the day of the storage)	Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation.
Quality of preservation of the sample	7 years (during all the duration of the collection)	The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure).

Trial Locations

Locations (5)

Service neurologie Centre hospitalier Fleyriat; 🇫🇷 Bourg-en-Bresse, France

Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer; 🇫🇷 Bron, France

Service de rythmologie, hôpital cardiologique Louis Pradel; 🇫🇷 Bron, France

Hôpital des charpennes; 🇫🇷 Villeurbanne, France

Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud; 🇫🇷 Pierre-Bénite, France